165 related articles for article (PubMed ID: 30318082)
21. Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC.
Rosell R; Neninger E; Nicolson M; Huber RM; Thongprasert S; Parikh PM; D'Hondt E
J Thorac Oncol; 2016 Nov; 11(11):1954-1961. PubMed ID: 27566188
[TBL] [Abstract][Full Text] [Related]
22. Repeated dose intramuscular injection of the CIMAvax-EGF vaccine in Sprague Dawley rats induces local and systemic toxicity.
Mancebo A; Casacó A; González B; Ledón N; Sorlozabal J; León A; Gómez D; González Y; Bada AM; González C; Arteaga ME; Ramírez H; Fuentes D
Vaccine; 2012 May; 30(22):3329-38. PubMed ID: 22433960
[TBL] [Abstract][Full Text] [Related]
23. Identifying predictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients.
Lorenzo-Luaces P; Sanchez L; Saavedra D; Crombet T; Van der Elst W; Alonso A; Molenberghs G; Lage A
BMC Cancer; 2020 Aug; 20(1):772. PubMed ID: 32807114
[TBL] [Abstract][Full Text] [Related]
24. Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario.
Flores Vega YI; Páramo González DL; Alsina Sarmiento SC; Alsina Tul LE; Inguanzo Valdés IB; Rodríguez Machado J; Elejalde Larrinaga Á; Flores Rodríguez JE; Lamadrid García J; Corrales Otero D; Ropero Toirac R; Crombet Ramos T; Gracia Medina EA
J Cancer; 2023; 14(5):874-879. PubMed ID: 37056397
[No Abstract] [Full Text] [Related]
25. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
[TBL] [Abstract][Full Text] [Related]
27. Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC.
Evans R; Lee K; Wallace PK; Reid M; Muhitch J; Dozier A; Mesa C; Luaces PL; Santos-Morales O; Groman A; Cedeno C; Cinquino A; Fisher DT; Puzanov I; Opyrchal M; Fountzilas C; Dai T; Ernstoff M; Attwood K; Hutson A; Johnson C; Mazorra Z; Saavedra D; Leon K; Lage A; Crombet T; Dy GK
Front Oncol; 2022; 12():958043. PubMed ID: 35992783
[TBL] [Abstract][Full Text] [Related]
28. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Silvestri GA; Rivera MP
Chest; 2005 Dec; 128(6):3975-84. PubMed ID: 16354869
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials.
González G; Crombet T; Neninger E; Viada C; Lage A
Hum Vaccin; 2007; 3(1):8-13. PubMed ID: 17204867
[TBL] [Abstract][Full Text] [Related]
30. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
31. The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer.
Crombet Ramos T; Santos Morales O; Dy GK; León Monzón K; Lage Dávila A
Front Oncol; 2021; 11():639745. PubMed ID: 34211836
[TBL] [Abstract][Full Text] [Related]
32. ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells.
Kol A; Terwisscha van Scheltinga A; Pool M; Gerdes C; de Vries E; de Jong S
Oncotarget; 2017 Jul; 8(28):45432-45446. PubMed ID: 28467975
[TBL] [Abstract][Full Text] [Related]
33. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
34. Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines.
Raez LE; Santos ES; Mudad R; Podack ER
Expert Rev Anticancer Ther; 2005 Aug; 5(4):635-44. PubMed ID: 16111464
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic vaccination with an EGF-based vaccine in lung cancer: a step in the transition to a chronic disease.
Rodriguez G; Gonzalez G; Crombet T; Lage A
Expert Rev Respir Med; 2011 Jun; 5(3):337-42. PubMed ID: 21702656
[TBL] [Abstract][Full Text] [Related]
36. Are vaccines making a comeback in non-small-cell lung cancer?
Nemunaitis JJ
J Clin Oncol; 2008 Mar; 26(9):1402-3. PubMed ID: 18349390
[No Abstract] [Full Text] [Related]
37. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
Stabile LP; Lyker JS; Gubish CT; Zhang W; Grandis JR; Siegfried JM
Cancer Res; 2005 Feb; 65(4):1459-70. PubMed ID: 15735034
[TBL] [Abstract][Full Text] [Related]
38. Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients.
Rodriguez PC; Neninger E; García B; Popa X; Viada C; Luaces P; González G; Lage A; Montero E; Crombet T
J Immune Based Ther Vaccines; 2011 Oct; 9():7. PubMed ID: 22024351
[TBL] [Abstract][Full Text] [Related]
39. Clinical relevance of monoclonal antibodies in non small cell lung cancer.
Filipits M
J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057
[TBL] [Abstract][Full Text] [Related]
40. CIMAvax EGF vaccine for stage IIIb/IV non-small cell lung carcinoma.
Cheng JY; Kananathan R
Hum Vaccin Immunother; 2012 Dec; 8(12):1799-801. PubMed ID: 22906936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
